Search

Your search keyword '"Generalized anxiety disorder -- Drug therapy"' showing total 65 results
Start Over Descriptor "Generalized anxiety disorder -- Drug therapy"
65 results on '"Generalized anxiety disorder -- Drug therapy"'

1. LSD Drug Candidate Gets Breakthrough Tx Status for Generalized Anxiety Disorder

Author

Park, Brian

Subjects
United States. Food and Drug Administration, Drug therapy, Generalized anxiety disorder -- Drug therapy, Tranquilizing agents, LSD (Drug), Tranquilizing drugs
Abstract

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to MM120 (lysergide d-tartrate) for the treatment of generalized anxiety disorder (GAD). MM120 is a tartrate salt form of [...]

Published
2024

2. Data on Generalized Anxiety Disorders Described by Researchers at Central Michigan University (Fecal Microbiota Transplant On escherichia-shigella Gut Composition and Its Potential Role In the Treatment of Generalized Anxiety Disorder

Subjects
Drug therapy, Generalized anxiety disorder -- Drug therapy, Microbiota (Symbiotic organisms), Mental health
Abstract

2024 JUN 10 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- A new study on Mental Health Diseases and Conditions - Generalized Anxiety Disorders [...]

Published
2024

3. FDA Grants Breakthrough Therapy Designation to LSD-Based Treatment for Generalized Anxiety Disorder: Mind Medicine's lysergide d-tartrate (MM-120) demonstrated statistically significant and clinically meaningful improvements in anxiety symptoms in findings from a phase 2b study

Author

Meara, Killian

Subjects
Drug therapy, Generalized anxiety disorder -- Drug therapy, LSD (Drug)
Abstract

Mind Medicine has received breakthrough therapy designation from the FDA for its lysergide d-tartrate (MM-120) therapy to treat patients with generalized anxiety disorder (GAD), the biopharmaceutical company announced in a [...]

Published
2024

4. Lexapro Approved for Generalized Anxiety Disorder in Children

Author

Ernst, Diana

Subjects
United States. Food and Drug Administration, Lexapro (Medication), Drug therapy, Generalized anxiety disorder -- Drug therapy, Child health, Pediatrics, Drug approval, Escitalopram, Children -- Health aspects
Abstract

The Food and Drug Administration (FDA) has approved Lexapro (escitalopram) for the treatment of generalized anxiety disorder (GAD) in pediatric patients 7 years of age and older. Previously, the treatment [...]

Published
2023

5. Buspirone for the Treatment of Generalized Anxiety Disorder in Williams Syndrome: A Case Series

Author

Thom, Robyn P., Keary, Christopher J., Waxler, Jessica L., Pober, Barbara R., and McDougle, Christopher J.

Subjects
Drug therapy, Testing, Case studies, Generalized anxiety disorder -- Drug therapy, Williams syndrome -- Drug therapy -- Case studies, Buspirone -- Testing, Buspirone hydrochloride -- Testing
Abstract

Author(s): Robyn P. Thom [sup.1] [sup.3] , Christopher J. Keary [sup.1] [sup.2] [sup.3] , Jessica L. Waxler [sup.1] , Barbara R. Pober [sup.1] [sup.4] , Christopher J. McDougle [sup.1] [sup.2] [...], Co-morbid anxiety disorders, including generalized anxiety disorder (GAD), are highly prevalent among individuals with Williams syndrome (WS). However, reports of the pharmacologic treatment of only a limited number of previous anxiety disorders in WS have appeared in the literature. Here, we review the case histories of three adolescents/young adults with WS and the treatment course of co-morbid GAD with buspirone. Treatment with buspirone was well-tolerated and resulted in sustained response in all three cases. Common medical disorders in WS are highlighted with regards to safe and appropriate pharmacologic treatment of GAD. Buspirone's generally benign side effect profile is a major benefit of its use for treating GAD in individuals with WS.

Published
2020
Full Text
View/download PDF

6. MindMed Announces Positive Results from Collaborators' Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal

Subjects
Testing, Drug therapy, Product development, Generalized anxiety disorder -- Drug therapy, LSD (Drug) -- Testing, Biotechnology industries -- Product development, Biotechnology industry -- Product development
Abstract

2022 SEP 24 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the 'Company' or 'MindMed'), [...]

Published
2022

7. Research on Anxiety Disorders Detailed by a Researcher at Pondicherry Institute of Medical Sciences (Prevalence of generalized anxiety disorder among patients attending medicine outpatient department in a tertiary care center: A cross-sectional ...)

Subjects
Drug therapy, Generalized anxiety disorder -- Drug therapy, Mental health
Abstract

2024 FEB 12 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- New study results on anxiety disorders have been published. According to news reporting [...]

Published
2024

8. Sunovion & Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder

Subjects
Sunovion Pharmaceuticals Inc., Generalized anxiety disorder -- Drug therapy, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

MARLBOROUGH: Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) today announced that the first patient has been randomized in a Phase 2/3 clinical study evaluating ulotaront, [...]

Published
2023

9. Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder

Subjects
Sunovion Pharmaceuticals Inc., Otsuka Holdings Company Ltd., Otsuka Pharmaceutical Company Ltd., Generalized anxiety disorder -- Drug therapy, Health products industry, Pharmaceutical industry, Business, Business, international
Abstract

-Approximately 7.5 Million People in The U.S. Are Living with Generalized Anxiety Disorder (GAD) 1,2- MARLBOROUGH, Mass. & PRINCETON, N.J. -- Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & [...]

Published
2023

11. FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

Subjects
United States. Food and Drug Administration, Generalized anxiety disorder -- Drug therapy, Clinical trials, General interest, News, opinion and commentary
Abstract

NEW YORK: Mind Medicine (MindMed) Inc has issued the following news release: Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the 'Company'), a clinical-stage biopharmaceutical company developing psychedelic-inspired [...]

Published
2022

12. FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

Subjects
United States. Food and Drug Administration, Generalized anxiety disorder -- Drug therapy, Clinical trials, Business, News, opinion and commentary
Abstract

- FDA clearance leads to first commercialINDfor LSD, enabling initiation of Phase 2b dose-optimization trial of MM-120 in early 2022 - NEW YORK, Jan. 25, 2022 /PRNewswire/ --Mind Medicine (MindMed) [...]

Published
2022

13. MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder

Subjects
United States. Food and Drug Administration, Generalized anxiety disorder -- Drug therapy, Clinical trials, LSD (Drug) -- Product development, General interest, News, opinion and commentary
Abstract

NEW YORK: Mind Medicine (MindMed) Inc. has issued the following news release: Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the 'Company'), a leading biotech company developing psychedelic-inspired [...]

Published
2021

14. MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder

Subjects
United States. Food and Drug Administration, Generalized anxiety disorder -- Drug therapy, Clinical trials, LSD (Drug) -- Product development, Business, News, opinion and commentary
Abstract

- FDA has issued a clinical hold on initial IND submission required to initiate Phase 2b trial of LSD for the treatment of generalized anxiety disorder - NEW YORK, Dec. [...]

Published
2021

15. New Findings from Yunnan in the Area of Generalized Anxiety Disorders Published (Analysis of the Underlying Mechanism of the Jiu Wei Zhen Xin Formula for Treating Generalized Anxiety Disorder Based on Network Pharmacology of Traditional Chinese ...)

Subjects
Drug therapy, International economic relations, Reports, Generalized anxiety disorder -- Drug therapy, Evidence-based medicine -- Reports
Abstract

2022 JUN 13 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- New study results on generalized anxiety disorders have been published. According to news [...]

Published
2022

16. Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release

Author

Rickels, Karl, Etemad, Bijan, Khalid-Khan, Sarosh, Lohoff, Falk W., Rynn, Moira A., and Gallop, Robert J.

Subjects
Generalized anxiety disorder -- Drug therapy, Generalized anxiety disorder -- Complications and side effects, Generalized anxiety disorder -- Research, Venlafaxine -- Dosage and administration, Venlafaxine -- Research, Diseases -- Relapse, Diseases -- Reports, Health, Psychology and mental health
Published
2010

19. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials

Author

Martin, Jose Luis R., Sainz-Pardo, MarAa, Furukawa, Toshiaki A., MartAn-Sanchez, Eva, Seoane, Teresa, and Gal±n, Cristina

Subjects
Drug therapy, Observations, Evaluation, Benzodiazepines -- Evaluation, Generalized anxiety disorder -- Drug therapy, Meta-analysis, Treatment refusal -- Observations, Right to refuse treatment -- Observations
Abstract

Introduction Generalized anxiety disorder (GAD) is characterized by excessive worry and anxiety sustained over a period of time exceeding 6 months, and leads to severe impairment of different spheres of [...], No systematic review or meta-analysis using a hard outcome has been conducted on the role of benzodiazepines for generalized anxiety disorder (GAD). The objective of this study was to assess the effectiveness and efficacy of benzodiazepines in the treatment of GAD based on trial drop-out rates. We used a systematic review of randomized controlled trials that compared any of the three best established benzodiazepines (diazepam, lorazepam and alprazolam) against placebo. Our primary outcome for effectiveness was withdrawal for any reason. Our secondary outcome tapping efficacy was withdrawal due to lack of efficacy, and that tapping side effects was withdrawals due to adverse events. We included 23 trials. Pooled analysis indicated less risk of treatment discontinuation due to lack of efficacy for benzodiazepines, compared to placebo, relative risk (RR) 0.29 (95% CI 0.18-0.45; p This systematic review did not find convincing evidence of the short-term effectiveness of the benzodiazepines in the treatment of GAD. On the other hand, for the outcome of efficacy, this review found robust evidence in favour of benzodiazepines. Due to the heterogeneity induced by year of publication, three hypotheses are plausible when it comes to being able to account for the differences between efficacy and effectiveness observed in the outcomes (publication bias, quality of the trial literature and a non-differential response to the placebo effect). Keywords generalized anxiety disorder, benzodiazepines, systematic review, clinical trial

Published
2007

21. Meta-analysis of cognitive--behavioral treatments for generalized anxiety disorder: a comparison with pharmacotherapy

Author

Mitte, Kristin

Subjects
Generalized anxiety disorder -- Care and treatment, Generalized anxiety disorder -- Drug therapy, Cognitive therapy -- Comparative analysis, Cognitive therapy -- Evaluation, Psychology and mental health
Abstract

The efficacy of (cognitive) behavioral therapy ([C]BT) for generalized anxiety disorder was investigated and compared with the efficacy of pharmacological therapy using meta-analytic techniques. A total of 65 (C)BT studies and pharmacological studies were included. (C)BT was more effective than control conditions. The results of the comparison between (C)BT and pharmacotherapy varied according to the meta-analytic methods used. Conclusions about differences in efficacy between therapy approaches are limited when all available studies are included owing to a number of factors that influence effect sizes. When only those studies that directly compared both therapies were included in the analysis, there were no significant differences in efficacy. Attrition rates were lower for (C)BT, indicating that it is better tolerated by patients. Keywords: generalized anxiety disorder, cognitive--behavior therapy, drug therapy, meta-analysis

Published
2005

22. Investigators from Massachusetts General Hospital Report New Data on Down Syndrome (Buspirone for the Treatment of Generalized Anxiety Disorder In Down Syndrome: 3 Cases)

Subjects
Massachusetts General Hospital -- Reports -- Statistics, Statistics, Drug therapy, Reports, Generalized anxiety disorder -- Drug therapy, Down syndrome -- Drug therapy, Central nervous system depressants -- Statistics, Mental health -- Reports -- Statistics
Abstract

2022 JAN 17 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- New research on Genetic Diseases and Conditions - Down Syndrome is the subject [...]

Published
2022

23. Investigators at Sun Yat-sen University Detail Findings in Generalized Anxiety Disorders (Disruption of Functional and Structural Networks In First -episode, Drug -nave Adolescents With Generalized Anxiety Disorder)

Subjects
Drug therapy, Diseases, Generalized anxiety disorder -- Drug therapy, Youth, Mental health, Teenagers
Abstract

2021 APR 12 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Current study results on Mental Health Diseases and Conditions - Generalized Anxiety Disorders [...]

Published
2021

24. Escitalopram, oral

Subjects
Lexapro (Medication) -- Complications and side effects -- Dosage and administration, Drug therapy, Complications and side effects, Dosage and administration, Depression (Mood disorder) -- Drug therapy, Generalized anxiety disorder -- Drug therapy, Escitalopram -- Dosage and administration -- Complications and side effects, Depression, Mental -- Drug therapy
Abstract

eh-sigh-TAL-oh-pram What are other names for this medicine? Type of medicine: selective serotonin reuptake inhibitor (SSRI); antidepressant Generic and brand names: escitalopram, oral; Lexapro What is this medicine used for? [...]

Published
2010

25. Investigators at Sun Yat-sen University Report New Data on Anxiety Disorders (White matter structural network disturbances in first-episode, drug-naive adolescents with generalized anxiety disorder)

Subjects
Drug therapy, Diseases, Reports, Generalized anxiety disorder -- Drug therapy, Youth -- Reports, Mental health -- Reports
Abstract

2020 OCT 26 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Fresh data on Mental Health Diseases and Conditions - Anxiety Disorders are presented [...]

Published
2020

26. New Generalized Anxiety Disorders Study Results from Mayo Clinic Described (Novel Pharmacological Treatments for Generalized Anxiety Disorder: Pediatric Considerations)

Subjects
Drug therapy, Generalized anxiety disorder -- Drug therapy, Eszopiclone, Child health, Mental health, Pimavanserin, Anxiety, Finance, Youth, Editors, Diseases
Abstract

2020 JUN 8 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Researchers detail new data in Mental Health Diseases and Conditions - Generalized Anxiety [...]

Published
2020

27. GAD: pregabalin shows promise as non-addictive anxiolytic. (Drugs in the Pipeline)

Subjects
Drug therapy, Evaluation, Generalized anxiety disorder -- Drug therapy, Antianxiety agents -- Evaluation
Abstract

The novel agent, pregabalin, is as effective as the most commonly used benzodiazepine for the treatment of generalized anxiety disorder, without its withdrawal effects, Atul Pande, M.D., and colleagues reported [...]

Published
2003

28. A pilot study of the effects of chronic paroxetine administration on hippocampal N-acetylaspartate in generalized anxiety disorder

Author

Mathew, S.J., Price, R.B., Shungu, D.C., X. Mao, Smith, ELP, Amiel, J.M., and Coplan, J.D.

Subjects
Generalized anxiety disorder -- Diagnosis, Generalized anxiety disorder -- Drug therapy, Paroxetine -- Dosage and administration, Magnetic resonance imaging -- Usage, Hippocampus (Brain) -- Health aspects, Pharmaceuticals and cosmetics industries, Psychology and mental health
Published
2010

29. New Findings from University of Pittsburgh School of Medicine in the Area of Anxiety Disorders Reported (When worry may be good for you: Worry severity and limbic-prefrontal functional connectivity in late-life generalized anxiety disorder)

Subjects
Elsevier Science B.V., University of Pittsburgh. School of Medicine, Drug therapy, Diseases, Periodical publishing, Generalized anxiety disorder -- Drug therapy, Mental health, Anxiety, Elderly, Brain research, Editors
Abstract

2019 AUG 12 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Current study results on Mental Health Diseases and Conditions - Anxiety Disorders have [...]

Published
2019

30. GeneSight(R) Shown to Statistically Significantly Improve Generalized Anxiety Disorder Treatment Response and Decrease Benzodiazepine Use

Subjects
Myriad Genetics Inc., Benzodiazepines, Generalized anxiety disorder -- Drug therapy, Biotechnology industries, Banking, finance and accounting industries, Business, University of Toronto. Centre for Addiction and Mental Health
Abstract

SALT LAKE CITY, Oct 19, 2017 (GLOBE NEWSWIRE via COMTEX) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced new positive results for the GeneSighttest in [...]

Published
2017

32. OTC: New prescribing information: Cipralex

Subjects
Lundbeck Ltd. -- Product development, Generalized anxiety disorder -- Drug therapy, Antianxiety agents -- Product development, Antianxiety agents -- Dosage and administration, Chemicals, plastics and rubber industries, Pharmaceuticals and cosmetics industries, Cipralex (Medication) -- Dosage and administration
Abstract

Escitalopram 5mg, 10mg and 20mg tablets Licensed for the treatment of generalised anxiety disorder. Usual dose: 10mg once daily, increasing to 20mg daily if needed. Lundbeck Ltd. Tel: 01908 649966 [...]

Published
2006

33. Escitalopram

Subjects
Lexapro (Medication) -- Dosage and administration, Drug therapy, Dosage and administration, Generalized anxiety disorder -- Drug therapy, Drug approval
Abstract

Escitalopram (Lexapro, Forest) was approved for the treatment of generalized anxiety [...]

Published
2004

34. Findings on Pharmacology Reported by Investigators at Institute of Diabetes (Profile of agomelatine and its potential in the treatment of generalized anxiety disorder)

Subjects
Drug therapy, Pharmacology, Generalized anxiety disorder -- Drug therapy, Diabetes mellitus -- Drug therapy, Diabetes therapy
Abstract

By a News Reporter-Staff News Editor at Biotech Week -- A new study on Pharmacology is now available. According to news reporting originating in Rio de Janeiro, Brazil, by NewsRx [...]

Published
2015

36. Sepracor Reports Preliminary Phase II Study Results for SEP-225441 for the Treatment of Generalized Anxiety Disorder

Subjects
Sepracor Inc. -- Product development, Generalized anxiety disorder -- Drug therapy, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced that it has completed the analysis and validation of the preliminary results of a Phase II, 440-patient study evaluating the efficacy [...]

Published
2009

37. Approved: duloxetine for generalized anxiety disorder

Subjects
Eli Lilly and Co., Drug therapy, Generalized anxiety disorder -- Drug therapy, Pharmaceutical industry
Abstract

On February 23, the FDA announced the approval of a new indication for Eli Lilly's antidepressant Cymbalta (duloxetine HCl): generalized anxiety disorder (GAD) in adults. The serotonin and norepinephrine reuptake [...]

Published
2007

38. Cymbalta for GAD

Subjects
Eli Lilly and Co. -- Product development -- Licensing, certification and accreditation, Cymbalta (Medication) -- Licensing, certification and accreditation -- Product development, Drug therapy, Licensing, certification and accreditation, Product development, Generalized anxiety disorder -- Drug therapy, Pharmaceutical industry -- Product development -- Licensing, certification and accreditation, Duloxetine -- Licensing, certification and accreditation -- Product development
Abstract

Cymbalta (duloxetine HCl, from Lilly) has gained an indication for the treatment of generalized anxiety disorder (GAD). This serotonin and norepinephrine reuptake inhibitor is already indicated for the treatment of [...]

Published
2007

39. Passion flower vs. Xanax

Author

Rountree, Robert

Subjects
Passion flower -- Usage, Passion flower -- Complications and side effects, Medicinal plants -- Health aspects, Medicinal plants -- Complications and side effects, Generalized anxiety disorder -- Drug therapy, Health, Xanax (Medication) -- Complications and side effects
Published
2005

40. Escitalopram eases GAD

Author

Foley, Kevin

Subjects
Drug therapy, Dosage and administration, Generalized anxiety disorder -- Drug therapy, Escitalopram -- Dosage and administration
Abstract

Escitalopram is an effective and well-tolerated option for patients with generalized anxiety disorder, reported Siegfried Kasper, M.D., of the University of Vienna, and associates. In a 12-week double-blind trial, 145 [...]

Published
2005

41. Social phobia patients respond well to fluoxetine; less effective for anxiety

Author

Evans, Jeff

Subjects
Drug therapy, Evaluation, Social phobia -- Drug therapy, Generalized anxiety disorder -- Drug therapy, Fluoxetine -- Evaluation
Abstract

Children with social phobia or generalized anxiety disorder responded clinically to fluoxetine, but those with social phobia were the only ones who had significant functional response to fluoxetine, according to [...]

Published
2003

42. Anxiety disorders improved with Escitalopram. (Recently Approved)

Author

Boschert, Sherry

Subjects
Drug therapy, Evaluation, Social phobia -- Drug therapy, Generalized anxiety disorder -- Drug therapy, Panic disorder -- Drug therapy, Selective serotonin reuptake inhibitors -- Evaluation, Panic attacks -- Drug therapy, Serotonin uptake inhibitors -- Evaluation, Panic disorders -- Drug therapy
Abstract

YOKOHAMA, JAPAN -- The new antidepressant drug escitalopram is effective in treating panic disorder, generalized anxiety disorder, and social anxiety disorder, several investigators reported in poster presentations at the 12th [...]

Published
2003

43. Pfizer Reports Top-Line Results of EU Post-Authorization Safety and Efficacy Study of Lyrica's Discontinuation Effects In Patients with Generalized Anxiety Disorder

Subjects
Pfizer Inc., Drug therapy, Diseases, Generalized anxiety disorder -- Drug therapy, Drugs, Pharmaceutical industry
Abstract

By a News Reporter-Staff News Editor at Biotech Week -- Pfizer Inc. (NYSE: PFE) announced that top-line results for Lyrica® (pregabalin) capsules Study A0081147 - Long Term Safety and Efficacy [...]

Published
2012

44. Practical psychopharmacology. (Psychopharmacology)

Author

Sherman, Carl

Subjects
Practice, Drug therapy, Generalized anxiety disorder -- Drug therapy, Psychopharmacology -- Practice
Abstract

Remission Should Be Goal of GAD Treatment Generalized anxiety disorder has long been a diagnosis in process. Only with DSM-III-R did it become more than a residual disorder; in later [...]

Published
2002

45. FDA Approves Cymbalta for Maintenance Treatment of Generalized Anxiety Disorder

Subjects
Eli Lilly and Co., United States. Food and Drug Administration, Cymbalta (Medication), Drug therapy, Diseases, Generalized anxiety disorder -- Drug therapy, Drugs, Pharmaceutical industry, Drug approval, Anxiety -- Drug therapy
Abstract

The U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, Eli Lilly and Company (NYSE:LLY) announced (see [...]

Published
2009

46. FDA Approves Cymbalta® for Maintenance Treatment of Generalized Anxiety Disorder

Subjects
Eli Lilly and Co., United States. Food and Drug Administration, Cymbalta (Medication), Drug therapy, Diseases, Generalized anxiety disorder -- Drug therapy, Drug approval, Pharmaceutical industry
Abstract

The U.S. Food and Drug Administration (FDA) has approved Cymbalta=AE (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, Eli Lilly and Company (NYSE:LLY) announced (see [...]

Published
2009

47. Sepracor reports preliminary Ph II SEP-225441 results in GAD

Subjects
Sepracor Inc. -- Product development, SEP-225441 (Medication) -- Product development, Drug therapy, Product development, Generalized anxiety disorder -- Drug therapy, Eszopiclone -- Product development, Pharmaceutical industry -- Product development
Abstract

USA firm Sepracor has completed the analysis and validation of the preliminary results of a Phase II, 440-patient study evaluating the efficacy and safety of SEP-225441, a modified-release formulation of [...]

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results